Alopecia Areata clinical trials at UC Davis
1 research study open to eligible people
A Study of Experimetnal Baricitinib (LY3009104) for Severe or Very Severe Alopecia Areata (sudden hair loss)
open to eligible people ages 18-70
This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.
Sacramento, California and other locations